What is Xeris Biopharma Holdings, Inc.'s market cap?

Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.4B and trades on NASDAQ.

What is Xeris Biopharma Holdings, Inc.'s revenue and profitability?

Xeris Biopharma Holdings, Inc. generated $314.9M in trailing twelve-month revenue with net income of $12.0M, representing a net margin of 3.8%. Gross margin stands at 85.9%. These figures are based on the Q1 2026 filing.

Who are Xeris Biopharma Holdings, Inc.'s competitors?

Xeris Biopharma Holdings, Inc.'s key competitors include Eli Lilly and Company, Eton Pharmaceutcials, Inc. Common Stock, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

What subsidiaries does Xeris Biopharma Holdings, Inc. have?

Xeris Biopharma Holdings, Inc.'s subsidiaries include Strongbridge Biopharma plc.

Where is Xeris Biopharma Holdings, Inc. headquartered?

Xeris Biopharma Holdings, Inc. is headquartered in United States of America and employs approximately 377 people. It has been publicly traded since 2018.

Xeris Biopharma Holdings, Inc.

XERS

Xeris Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for patients with chronic endocrine and neurological diseases.

Market cap

$1.42B+72.5%

Revenue$314.9M+41.5%

Net income$12.0M+127%

EPS (diluted)$0.07+123%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$82.5MBeat by $2.6M EPS$0.01Beat by $0.01

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$90.1M

EPS estimate$0.02

Financials

Q1 2026

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

Valuation & ratios

Valuation

See full

Market cap$1.42B+72.5%

Enterprise value$1.56B+54.9%

P/E118×—

P/S4.5×+1.2×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Debt / equity19.9×—

Current ratio2.1×+0.4×

Segments

By product

See full

Recorlev$49.8M+94.9%

Gvoke$20.8M-0.2%

Keveyis$11.9M+4.0%

Royalty, contract and other revenue$673.0K-71.0%

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Neurocrine Biosciences$17.7B+34.0%

Ultragenyx Pharmaceutical$2.6B+1.5%

XER

Xeris Biopharma Holdings, Inc.$1.4B+74.6%

Eton Pharmaceuticals, Inc.$1.2B+188%

Zevra Therapeutics, Inc.$574.0M-2.9%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

SPR

Spruce Biosciences, Inc. $115.6M—

By revenue growth

Zevra Therapeutics, Inc.+201%

Eton Pharmaceuticals, Inc.+79.9%

Eli Lilly+47.4%

XER

Xeris Biopharma Holdings, Inc.+41.5%

Neurocrine Biosciences+28.6%

Ultragenyx Pharmaceutical+13.5%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Eli Lilly34.99%+12.3pp

Neurocrine Biosciences21.55%+8.9pp

XER

Xeris Biopharma Holdings, Inc.3.81%+24.1pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for patients with chronic endocrine and neurological diseases. The company utilizes its proprietary XeriSol and XeriJect non-aqueous formulation technologies to create ready-to-use, room-temperature stable injectable medicines. Their core value proposition lies in improving patient outcomes by making previously difficult-to-inject treatments more convenient and accessible.

Competitive position

Xeris maintains a competitive edge through proprietary non-aqueous formulation platforms and orphan drug exclusivity for its rare disease portfolio.

GeographiesUnited States

Customer segmentsSpecialty Healthcare Providers, Chronic Disease Patients, Pharmaceutical Partners

Business modelProduct-based, IP Licensing, Research and Development

SuppliersRaw material suppliers, Contract manufacturing organizations, Clinical research organizations

CustomersSpecialty pharmacies, Wholesale distributors, Third-party payors, Healthcare providers

CountryUnited States of America

Listed2018

Employees377.0

CEOJohn Shannon

SectorHealthcare

IndustryBiotechnology

Websitexerispharma.com

FilingsSEC EDGAR

Ask your AI about Xeris Biopharma Holdings, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s market cap?: Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.4B and trades on NASDAQ.
What is Xeris Biopharma Holdings, Inc.'s revenue and profitability?: Xeris Biopharma Holdings, Inc. generated $314.9M in trailing twelve-month revenue with net income of $12.0M, representing a net margin of 3.8%. Gross margin stands at 85.9%. These figures are based on the Q1 2026 filing.
Who are Xeris Biopharma Holdings, Inc.'s competitors?: Xeris Biopharma Holdings, Inc.'s key competitors include Eli Lilly and Company, Eton Pharmaceutcials, Inc. Common Stock, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
What subsidiaries does Xeris Biopharma Holdings, Inc. have?: Xeris Biopharma Holdings, Inc.'s subsidiaries include Strongbridge Biopharma plc.
Where is Xeris Biopharma Holdings, Inc. headquartered?: Xeris Biopharma Holdings, Inc. is headquartered in United States of America and employs approximately 377 people. It has been publicly traded since 2018.